Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma - PubMed (original) (raw)
Affiliations
- PMID: 9815833
Comparative Study
Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma
Y X Hu et al. Clin Cancer Res. 1997 Sep.
Abstract
Expression of the p16 gene product in human primary pancreatic carcinoma (PC) was investigated in paraffin-embedded tissue using a monoclonal antibody against p16 protein, clone G175-405, by means of immunohistochemistry, and the correlation of results with various clinicopathological parameters was evaluated. All six cases of normal pancreas and all but 1 of 20 cases of chronic pancreatitis expressed p16 protein, whereas 37.5% (3 of 8) of cystadenomas and 41. 9% (26 of 62) of PCs lost p16 expression. There was a significant difference between chronic pancreatitis and PC for frequency of the loss of p16 expression (P < 0.01). Moreover, loss of p16 expression in pancreatic malignancy was significantly associated with histological grade (G1 versus G2 and G3, P < 0.01) but not with sex, age, clinical stage, tumor location, or resectability. The survival period was shorter and metastasis is more likely in those cases that did not show p16 expression than those that did.
Similar articles
- Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters.
Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX, Motoo Y, Okai T, Sawabu N. Ohtsubo K, et al. J Gastroenterol. 2003;38(7):663-71. doi: 10.1007/s00535-003-1119-6. J Gastroenterol. 2003. PMID: 12898359 - An immunohistochemical study of p16, pRb, p21 and p53 proteins in human esophageal cancers.
Kato H, Yoshikawa M, Fukai Y, Tajima K, Masuda N, Tsukada K, Kuwano H, Nakajima T. Kato H, et al. Anticancer Res. 2000 Jan-Feb;20(1A):345-9. Anticancer Res. 2000. PMID: 10769678 - Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: a combined immunohistochemistry and image analysis study based on tissue microarrays.
Tsiambas E, Karameris A, Gourgiotis S, Salemis N, Athanassiou AE, Karakitsos P, Papalois A, Merikas E, Kosmidis P, Patsouris E. Tsiambas E, et al. J BUON. 2007 Apr-Jun;12(2):261-7. J BUON. 2007. PMID: 17600882 - p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ, McCluggage WG. O'Neill CJ, et al. Adv Anat Pathol. 2006 Jan;13(1):8-15. doi: 10.1097/01.pap.0000201828.92719.f3. Adv Anat Pathol. 2006. PMID: 16462152 Review. - Cystic tumors of the pancreas.
Albores-Saavedra J, Gould EW, Angeles-Angeles A, Henson DE. Albores-Saavedra J, et al. Pathol Annu. 1990;25 Pt 2:19-50. Pathol Annu. 1990. PMID: 2202959 Review. No abstract available.
Cited by
- P16-CD8-Ki67 Triple Algorithm for Prediction of CDKN2A Mutations in Patients with Multiple Primary and Familial Melanoma.
Nurla LA, Gheorghe E, Aşchie M, Cozaru GC, Orășanu CI, Boşoteanu M. Nurla LA, et al. Diagnostics (Basel). 2024 Apr 13;14(8):813. doi: 10.3390/diagnostics14080813. Diagnostics (Basel). 2024. PMID: 38667459 Free PMC article. - Expression Profile of KRAS and p16 in Periampullary Cancer.
Tewari M, Swain JR, Mishra RR, Dixit VK, Shukla HS. Tewari M, et al. Indian J Surg Oncol. 2024 Mar;15(1):25-34. doi: 10.1007/s13193-023-01819-4. Epub 2023 Sep 15. Indian J Surg Oncol. 2024. PMID: 38511045 - Asian-specific 3'UTR variant in CDKN2B associated with risk of pituitary adenoma.
Youn BJ, Cheong HS, Namgoong S, Kim LH, Baek IK, Kim JH, Yoon SJ, Kim EH, Kim SH, Chang JH, Kim SH, Shin HD. Youn BJ, et al. Mol Biol Rep. 2022 Nov;49(11):10339-10346. doi: 10.1007/s11033-022-07796-1. Epub 2022 Sep 12. Mol Biol Rep. 2022. PMID: 36097105 - In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration.
Bianchini M, Giambelluca M, Scavuzzo MC, Di Franco G, Guadagni S, Palmeri M, Furbetta N, Gianardi D, Costa A, Gentiluomo M, Gaeta R, Pollina LE, Falcone A, Vivaldi C, Di Candio G, Biagioni F, Busceti CL, Soldani P, Puglisi-Allegra S, Morelli L, Fornai F. Bianchini M, et al. Int J Mol Sci. 2022 Mar 29;23(7):3775. doi: 10.3390/ijms23073775. Int J Mol Sci. 2022. PMID: 35409135 Free PMC article. - Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?
Martinez-Useros J, Garcia-Foncillas J. Martinez-Useros J, et al. Biomed Res Int. 2016;2016:4873089. doi: 10.1155/2016/4873089. Epub 2016 Sep 1. Biomed Res Int. 2016. PMID: 27689078 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical